Abstract
Hepatocellular Carcinoma (HCC) is one of the most common malignancies, and its incidence and mortality are increasing worldwide. Cancer immunotherapy has revolutionized cancer treatment in recent years. In particular, immune checkpoint inhibitors (ICIs), as new therapeutic tools, have demonstrated encouraging antitumor activity and manageable tolerability in HCC. Immune checkpoint blockade with antibodies targeting Programmed cell Death-1 (PD-1), Programmed cell Death Ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated protein-4 (CTLA- 4) enhances tumor immunity by restoring exhausted T cells. Although the efficacy of combinational treatment strategies using ICIs combined with other ICIs, molecularly targeted agents, systemic therapy, or locoregional therapy has been well documented in numerous preclinical and clinical studies in several types of cancer, most HCC patients do not benefit from ICI treatment. This review highlights recent developments and potential opportunities related to ICIs and their combination in the management of HCC. The present article also reviews recent patents related to ICIs.
Keywords: Hepatocellular carcinoma, immunotherapy, immune checkpoint inhibitors, combination treatment, programmed cell death-1 (PD-1), cytotoxic T lymphocyte-Associated protein-4 (CTLA-4).
Recent Patents on Anti-Cancer Drug Discovery
Title:Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Volume: 16 Issue: 2
Author(s): Jing Bai, Ping Liang, Qian Li, Rui Feng*Jiang Liu*
Affiliation:
- Department of Pharmacy, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province,China
- Department of Pharmacy, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province,China
Keywords: Hepatocellular carcinoma, immunotherapy, immune checkpoint inhibitors, combination treatment, programmed cell death-1 (PD-1), cytotoxic T lymphocyte-Associated protein-4 (CTLA-4).
Abstract: Hepatocellular Carcinoma (HCC) is one of the most common malignancies, and its incidence and mortality are increasing worldwide. Cancer immunotherapy has revolutionized cancer treatment in recent years. In particular, immune checkpoint inhibitors (ICIs), as new therapeutic tools, have demonstrated encouraging antitumor activity and manageable tolerability in HCC. Immune checkpoint blockade with antibodies targeting Programmed cell Death-1 (PD-1), Programmed cell Death Ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated protein-4 (CTLA- 4) enhances tumor immunity by restoring exhausted T cells. Although the efficacy of combinational treatment strategies using ICIs combined with other ICIs, molecularly targeted agents, systemic therapy, or locoregional therapy has been well documented in numerous preclinical and clinical studies in several types of cancer, most HCC patients do not benefit from ICI treatment. This review highlights recent developments and potential opportunities related to ICIs and their combination in the management of HCC. The present article also reviews recent patents related to ICIs.
Export Options
About this article
Cite this article as:
Bai Jing , Liang Ping , Li Qian , Feng Rui *, Liu Jiang *, Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma, Recent Patents on Anti-Cancer Drug Discovery 2021; 16 (2) . https://dx.doi.org/10.2174/1574892816666210212145107
DOI https://dx.doi.org/10.2174/1574892816666210212145107 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetic Metalloenzymes
Current Medicinal Chemistry Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology
Current Drug Targets Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery Journey Describing the Cytotoxic Potential of Withanolides: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry Medical Image Processing Technology for Diagnosing and Treating Cancers
Recent Patents on Biomedical Engineering (Discontinued) Pathophysiology of Erectile Dysfunction
Current Drug Targets Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine Cu-mediated synthesis of 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-1-ones as potential inhibitors of sirtuins
Letters in Drug Design & Discovery Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
Current Drug Metabolism UDP-Glucuronosyltransferases
Current Drug Metabolism Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Green Tea Catechins as Novel Antitumor and Antiangiogenic Compounds
Current Medicinal Chemistry - Anti-Cancer Agents Understanding Healthy Protective Mechanisms Against Old Age
Current Aging Science Proline-Directed Protein Kinase FA as a Potential Target for Diagnosis and Therapy of Human Cancers
Current Cancer Drug Targets Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design